The pharmacology and formulation of paliperidone extended release

References

• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23(8), 1296–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr. Res. 90(1–3), 229–237 (2007).
   PubMed Web of Science ®Google Scholar
• Chue P. Compliance and convenience; do physicians and patients see depot medication differrently? Acta Neuropsychiatrica 16, 314–338 (2004).
   PubMed Web of Science ®Google Scholar
• Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am. J. Psychiatry 159(1), 103–108 (2002).
   PubMed Web of Science ®Google Scholar
• Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin. Drug Investig. 24(5), 275–286 (2004).
   PubMed Web of Science ®Google Scholar
• Marino J, Caballero J. Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 28(10), 1283–1298 (2008).
   PubMed Web of Science ®Google Scholar
• Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am. J. Health. Syst. Pharm. 65(5), 403–413 (2008).
   PubMed Web of Science ®Google Scholar
• Owen RT. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today 43(4), 249–258 (2007).
   PubMed Web of Science ®Google Scholar
• Yang LP, Plosker GL. Paliperidone extended release. CNS Drugs 21(5), 417–425; discussion 426 (2007).
   PubMed Web of Science ®Google Scholar
• Dlugosz H, Nasrallah HA. Paliperidone: a new extended-release oral atypical antipsychotic. Expert Opin. Pharmacother. 8(14), 2307–2313 (2007).
   PubMed Web of Science ®Google Scholar
• Spina E, Cavallaro R. The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opin. Drug Saf. 6(6), 651–662 (2007).
   PubMed Web of Science ®Google Scholar
• Howland RH. Paliperidone extended-release tablets: a new atypical antipsychotic. J. Psychosoc. Nurs. Ment. Health Serv. 45(5), 15–18 (2007).
   Google Scholar
• Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr. Dis. Treat. 3(6), 869–897 (2007).
   PubMedGoogle Scholar
• Nussbaum A, Stroup TS. Paliperidone for schizophrenia. Cochrane Database Syst. Rev. 2, CD006369 (2008).
   Google Scholar
• Lautenschlager M, Heinz A. Paliperidone ER: first atypical antipsychotic with oral extended release formulation. Expert Rev. Neurother. 8(2), 193–200 (2008).
   PubMedGoogle Scholar
• Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 70(10), 1295–1317 (2010).
   PubMed Web of Science ®Google Scholar
• Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispos. 21(6), 1134–1141 (1993).
   PubMed Web of Science ®Google Scholar
• Meuldermans W, Hendrickx J, Mannens G et al. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab. Dispos. 22(1), 129–138 (1994).
   PubMed Web of Science ®Google Scholar
• European Medicines Evaluation Agency. Invega European Public Assessment Report. EMEA, London, UK. Scientific Discussion, 1–58 (2007).
   Google Scholar
• Cleton A, Rossenu S, Vermeulen A et al. A pharmacokinetic model to document the interconversion between paliperidone’s enantiomers. Clin. Pharmacol. Ther. 79, 55 (2006).
   Web of Science ®Google Scholar
• Locatelli I, Mrhar A, Grabnar I. Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detection. J. Pharm. Biomed. Anal. 50(5), 905–910 (2009).
   PubMed Web of Science ®Google Scholar
• Aravagiri M, Marder SR. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology 159(4), 424–431 (2002).
   PubMed Web of Science ®Google Scholar
• Aravagiri M, Yuwiler A, Marder SR. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 139(4), 356–363 (1998).
   PubMed Web of Science ®Google Scholar
• van Beijsterveldt LE, Geerts RJ, Leysen JE et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 114(1), 53–62 (1994).
   PubMed Web of Science ®Google Scholar
• Paliperidone, Product Monograph, Janssen-Ortho Inc., Toronto, ON, Canada. 26 September 2007, Revised 23 July 2009.
   Google Scholar
• Mannens G, Meuldermans W, Snoeck E, Heykants J. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology 114(4), 566–572 (1994).
   PubMed Web of Science ®Google Scholar
• Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch. Pharmacol. 359(2), 147–151 (1999).
   PubMed Web of Science ®Google Scholar
• Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug–drug interactions. Curr. Drug Metab. 9(5), 410–418 (2008).
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Mihara K, Kondo T et al. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J. Clin. Pharmacol. 43(2), 122–127 (2003).
   PubMed Web of Science ®Google Scholar
• Jung SM, Kim KA, Cho HK et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin. Pharmacol. Ther. 78(5), 520–528 (2005).
   PubMed Web of Science ®Google Scholar
• Vermeir M, Naessens I, Remmerie B et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab. Dispos. 36(4), 769–779 (2008).
   PubMed Web of Science ®Google Scholar
• Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr. Opin. Psychiatry 23(2), 103–111 (2010).
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL. Drug–drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol. Bull. 40(1), 77–97 (2007).
   PubMed Web of Science ®Google Scholar
• Saito M, Yasui-Furukori N, Nakagami T, Furukori H, Kaneko S. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J. Clin. Psychopharmacol. 25(6), 527–532 (2005).
   PubMed Web of Science ®Google Scholar
• Kang RH, Jung SM, Kim KA et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J. Clin. Psychopharmacol. 29(3), 272–277 (2009).
   PubMed Web of Science ®Google Scholar
• Aravagiri M, Marder SR, Nuechterlein KH, Gitlin MJ. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther. Drug Monit. 25(6), 657–664 (2003).
   PubMed Web of Science ®Google Scholar
• Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 147(3), 300–305 (1999).
   PubMed Web of Science ®Google Scholar
• Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40(3), 93–102 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou ZL, Li X, Peng HY et al. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol. Sin. 27(3), 381–386 (2006).
   PubMed Web of Science ®Google Scholar
• Yagihashi T, Mizuno M, Chino B et al. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum. Psychopharmacol. 24(4), 301–308 (2009).
   PubMed Web of Science ®Google Scholar
• Dunbar F, Chue P, Fu D, Huang Q, Franc M, Cohen N. Impact of CYP2D6 metabolizer phenotype on the safety profile of paliperidone ER. Presented at: Society of Biological Psychiatry 62nd Annual Convention. San Diego, CA, USA, 17–19 May 2007.
   Google Scholar
• Berwaerts J, Cleton A, Herben V et al. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 42(4), 158–163 (2009).
   PubMed Web of Science ®Google Scholar
• Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of risperidone. J. Clin. Pharmacol. 39(3), 297–309 (1999).
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Ueda N, Nakamura J. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology 44(3), 129–133 (2001).
   PubMed Web of Science ®Google Scholar
• Kakihara S, Yoshimura R, Shinkai K et al. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int. Clin. Psychopharmacol. 20(2), 71–78 (2005).
   PubMed Web of Science ®Google Scholar
• Riedel M, Schwarz MJ, Strassnig M et al. Risperidone plasma levels, clinical response and side-effects. Eur. Arch. Psychiatry Clin. Neurosci. 255(4), 261–268 (2005).
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciolà G et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 153(2), 238–243 (2001).
   PubMed Web of Science ®Google Scholar
• Aller SG, Yu J, Ward A et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323(5922), 1718–1722 (2009).
   PubMed Web of Science ®Google Scholar
• Dean M. The human ATP-binding cassette (ABC) transporter superfamily. National Library of Medicine (US), NCBI.
   Google Scholar
• Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31, 469–497 (2001).
   PubMed Web of Science ®Google Scholar
• Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J. Biol. Chem. 262(2), 505–508 (1987).
   PubMed Web of Science ®Google Scholar
• Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol. 7(4), 415–419 (2004).
   PubMed Web of Science ®Google Scholar
• Ejsing TB, Pedersen AD, Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug–drug interaction experiments. Hum. Psychopharmacol. 20(7), 493–500 (2005).
   PubMed Web of Science ®Google Scholar
• Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 71(2), 163–169 (2002).
   PubMed Web of Science ®Google Scholar
• Kirschbaum KM, Henken S, Hiemke C, Schmitt U. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav. Brain Res. 188(2), 298–303 (2008).
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 187(4), 415–423 (2006).
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology 32(4), 757–764 (2007).
   PubMed Web of Science ®Google Scholar
• Doran A, Obach RS, Smith BJ et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. 33(1), 165–174 (2005).
   PubMed Web of Science ®Google Scholar
• Pacchioni AM, Gabriele A, Donovan JL, DeVane CL, See RE. P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats. Int. J. Neuropsychopharmacol. 13(8), 1067–1077 (2010).
   PubMed Web of Science ®Google Scholar
• Feng B, Mills JB, Davidson RE et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos. 36(2), 268–275 (2008).
   PubMed Web of Science ®Google Scholar
• Xing Q, Gao R, Li H et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7(7), 987–993 (2006).
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Mihara K, Takahata T et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br. J. Clin. Pharmacol. 57(5), 569–575 (2004).
   PubMed Web of Science ®Google Scholar
• Saklad SR. Texas Department of Health Services Formulary Monograph Paliperidone Palmitate Extended-Release Injectable Suspension (Invega® Sustenna™).
   Google Scholar
• Bowden CR, Voina SJ, Woestenborghs R, De Coster R, Heykants J. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. J. Pharmacol. Exp. Ther. 262(2), 699–706 (1992).
   PubMed Web of Science ®Google Scholar
• De Clerck F, Somers Y, Mannaert E, Greenspan A, Eerdekens M. In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin. Ther. 26(8), 1261–1273 (2004).
   PubMed Web of Science ®Google Scholar
• Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin–dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 55(Suppl.), 5–12 (1994).
   PubMed Web of Science ®Google Scholar
• Arakawa R, Ito H, Takano A et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology 197(2), 229–235 (2008).
   PubMed Web of Science ®Google Scholar
• Karlsson P, Dencker E, Nyberg S et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies. Clinical. Pharmacol. Therap. 79, 74 (2005).
   Web of Science ®Google Scholar
• Megens AA, Awouters FH, Schotte A et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114(1), 9–23 (1994).
   PubMed Web of Science ®Google Scholar
• Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124(1–2), 57–73 (1996).
   PubMed Web of Science ®Google Scholar
• Knight JA, Smith C, Toohey N, Klein MT, Teitler M. Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-hydroxytryptamine7 receptor by risperidone, 9-OH-risperidone, and other inactivating antagonists. Mol. Pharmacol. 75(2), 374–380 (2009).
   PubMed Web of Science ®Google Scholar
• Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M. Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol. Pharmacol. 70(4), 1264–1270 (2006).
   PubMed Web of Science ®Google Scholar
• Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology 194(1), 63–72 (2007).
   PubMed Web of Science ®Google Scholar
• Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J. Cardiovasc. Pharmacol. 16(2), 276–285 (1990).
   PubMed Web of Science ®Google Scholar
• Vigneault P, Kaddar N, Bourgault S et al. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much? J. Cardiovasc. Pharmacol. 57(6), 690–695 (2011).
   PubMed Web of Science ®Google Scholar
• Titier K, Déridet E, Moore N. In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone. Toxicol. Appl. Pharmacol. 180(2), 145–149 (2002).
   PubMed Web of Science ®Google Scholar
• Llerena A, Berecz R, Dorado P, de la Rubia A. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J. Psychopharmacol. 18(2), 189–193 (2004).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Fukui N, Watanabe J et al. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. Hum. Psychopharmacol. 27(1), 39–42 (2012).
   PubMed Web of Science ®Google Scholar
• Nazirizadeh Y, Vogel F, Bader W et al. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur. J. Clin. Pharmacol. 66(8), 797–803 (2010).
   PubMed Web of Science ®Google Scholar
• Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr. Med. Res. Opin. 22(10), 1879–1892 (2006).
   PubMed Web of Science ®Google Scholar
• Boom S, Talluri K, Janssens L et al. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J. Clin. Pharmacol. 49(11), 1318–1330 (2009).
   PubMed Web of Science ®Google Scholar
• Boom S, Thyssen A, Crauwels H et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int. J. Clin. Pharmacol. Ther. 47(10), 606–616 (2009).
   PubMed Web of Science ®Google Scholar
• Aichhorn W, Weiss U, Marksteiner J et al. Influence of age and gender on risperidone plasma concentrations. J. Psychopharmacol. 19(4), 395–401 (2005).
   PubMed Web of Science ®Google Scholar
• Maxwell RA, Sweet RA, Mulsant BH et al. Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects. J. Geriatr. Psychiatry Neurol. 15(2), 77–81 (2002).
   PubMed Web of Science ®Google Scholar
• Si T, Shu L, Liu Y, Su YA, Guo C, Zhang H. Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. Hum. Psychopharmacol. 25(5), 404–409 (2010).
   PubMed Web of Science ®Google Scholar
• Thyssen A, Cleton A, Talluri K et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum. Psychopharmacol. 24(7), 532–539 (2009).
   PubMed Web of Science ®Google Scholar
• Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical antipsychotic metabolism and excretion. Curr. Drug Metab. 11(6), 516–525 (2010).
   PubMed Web of Science ®Google Scholar
• Eckert A. [Clinically relevant drug interactions with new generation antidepressants and antipsychotics]. Ther. Umsch. 66(6), 485–492 (2009).
   PubMedGoogle Scholar
• Ilett KF, Hackett LP, Kristensen JH, Vaddadi KS, Gardiner SJ, Begg EJ. Transfer of risperidone and 9-hydroxyrisperidone into human milk. Ann. Pharmacother. 38(2), 273–276 (2004).
   PubMed Web of Science ®Google Scholar
• Birnbaum M, Sharif Z. Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. Patient Prefer. Adherence 2, 233–240 (2008).
   PubMedGoogle Scholar
• Pani L, Marchese G. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opin. Drug Deliv. 6(3), 319–331 (2009).
   PubMed Web of Science ®Google Scholar
• de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 51(1), 80–88 (2010).
   PubMed Web of Science ®Google Scholar
• Dopheide JA. Paliperidone: an improvement over risperidone? Am. J. Health. Syst. Pharm. 65(5), 401 (2008).
   PubMed Web of Science ®Google Scholar
• Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent. Prescrire Int. 16(92), 236–237 (2007).
   PubMedGoogle Scholar
• Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evid. 2(4), 261–271 (2008).
   PubMedGoogle Scholar
• Citrome L. Paliperidone: quo vadis? Int. J. Clin. Pract. 61(4), 653–662 (2007).
   PubMed Web of Science ®Google Scholar
• Kramer M, Simpson G, Maciulis V et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 27(1), 6–14 (2007).
   PubMed Web of Science ®Google Scholar
• Peuskens J, Trivedi J, Malyarov S et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebocontrolled trial in clinically stable patients. Psychiatry 4(11), 34–50 (2007).
   PubMedGoogle Scholar
• Gendron A, Schweikert C, Ganesan S et al. A multicentre, international, open-label, prospective long-term study evaluating the clinical benefit and effectiveness of switching to quetiapine extended release in subjects with schizophrenia. Presented at: 61st Annual Meeting of the Canadian Psychiatric Association. Vancouver, BC, Canada, 13 – 17 October 2011.
   Google Scholar